RxSight (RXST) Competitors

$6.09 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$6.08 0.00 (-0.08%)

As of 05/22/2026 04:10 PM Eastern

RXST vs. BFLY, TNDM, DRTS, INMD, and BVS

Should you buy RxSight stock or one of its competitors? MarketBeat compares RxSight with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RxSight include Butterfly Network (BFLY), Tandem Diabetes Care (TNDM), Alpha Tau Medical (DRTS), InMode (INMD), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.

How does RxSight compare to Butterfly Network?

RxSight (NASDAQ:RXST) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

RxSight currently has a consensus price target of $9.44, suggesting a potential upside of 55.08%. Butterfly Network has a consensus price target of $5.56, suggesting a potential upside of 24.41%. Given RxSight's higher possible upside, equities research analysts plainly believe RxSight is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Butterfly Network had 1 more articles in the media than RxSight. MarketBeat recorded 3 mentions for Butterfly Network and 2 mentions for RxSight. RxSight's average media sentiment score of 0.52 beat Butterfly Network's score of 0.51 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight has a net margin of -36.58% compared to Butterfly Network's net margin of -73.63%. RxSight's return on equity of -17.01% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Butterfly Network	-73.63%	-34.41%	-23.91%

78.8% of RxSight shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 25.2% of Butterfly Network shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

RxSight has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.87	-$38.94M	-$1.13	N/A
Butterfly Network	$97.61M	11.66	-$77.06M	-$0.30	N/A

RxSight has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

Summary

RxSight beats Butterfly Network on 9 of the 16 factors compared between the two stocks.

How does RxSight compare to Tandem Diabetes Care?

RxSight (NASDAQ:RXST) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

RxSight has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.87	-$38.94M	-$1.13	N/A
Tandem Diabetes Care	$1.01B	1.01	-$204.71M	-$1.40	N/A

RxSight presently has a consensus target price of $9.44, indicating a potential upside of 55.08%. Tandem Diabetes Care has a consensus target price of $29.63, indicating a potential upside of 97.94%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52

Tandem Diabetes Care has a net margin of -9.20% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

RxSight has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

In the previous week, RxSight and RxSight both had 2 articles in the media. RxSight's average media sentiment score of 0.52 beat Tandem Diabetes Care's score of 0.06 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight and Tandem Diabetes Care tied by winning 8 of the 16 factors compared between the two stocks.

How does RxSight compare to Alpha Tau Medical?

RxSight (NASDAQ:RXST) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Alpha Tau Medical had 14 more articles in the media than RxSight. MarketBeat recorded 16 mentions for Alpha Tau Medical and 2 mentions for RxSight. RxSight's average media sentiment score of 0.52 beat Alpha Tau Medical's score of 0.00 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Tau Medical	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

RxSight has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Alpha Tau Medical has a net margin of 0.00% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Alpha Tau Medical	N/A	-73.23%	-52.90%

78.8% of RxSight shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 10.1% of RxSight shares are owned by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RxSight currently has a consensus price target of $9.44, indicating a potential upside of 55.08%. Alpha Tau Medical has a consensus price target of $11.50, indicating a potential upside of 14.54%. Given RxSight's higher probable upside, research analysts clearly believe RxSight is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

RxSight has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.87	-$38.94M	-$1.13	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A

Summary

RxSight beats Alpha Tau Medical on 9 of the 15 factors compared between the two stocks.

How does RxSight compare to InMode?

RxSight (NASDAQ:RXST) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

InMode has a net margin of 23.27% compared to RxSight's net margin of -36.58%. InMode's return on equity of 13.47% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
InMode	23.27%	13.47%	11.95%

InMode has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.87	-$38.94M	-$1.13	N/A
InMode	$370.49M	2.35	$93.83M	$1.36	10.10

RxSight has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, InMode has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

In the previous week, InMode had 1 more articles in the media than RxSight. MarketBeat recorded 3 mentions for InMode and 2 mentions for RxSight. RxSight's average media sentiment score of 0.52 beat InMode's score of 0.00 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMode	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.8% of RxSight shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

RxSight currently has a consensus target price of $9.44, indicating a potential upside of 55.08%. InMode has a consensus target price of $16.00, indicating a potential upside of 16.45%. Given RxSight's higher possible upside, analysts plainly believe RxSight is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

InMode beats RxSight on 11 of the 16 factors compared between the two stocks.

How does RxSight compare to Bioventus?

Bioventus (NASDAQ:BVS) and RxSight (NASDAQ:RXST) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Bioventus presently has a consensus price target of $14.00, suggesting a potential upside of 50.86%. RxSight has a consensus price target of $9.44, suggesting a potential upside of 55.08%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

In the previous week, Bioventus had 1 more articles in the media than RxSight. MarketBeat recorded 3 mentions for Bioventus and 2 mentions for RxSight. RxSight's average media sentiment score of 0.52 beat Bioventus' score of 0.00 indicating that RxSight is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.9% of Bioventus shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bioventus has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, RxSight has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Bioventus has a net margin of 4.94% compared to RxSight's net margin of -36.58%. Bioventus' return on equity of 29.97% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
RxSight	-36.58%	-17.01%	-15.12%

Bioventus has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.36	$22.73M	$0.41	22.63
RxSight	$134.48M	1.87	-$38.94M	-$1.13	N/A

Summary

Bioventus beats RxSight on 12 of the 17 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$251.90M	$7.10B	$6.45B	$12.34B
Dividend Yield	N/A	1.68%	2.76%	5.28%
P/E Ratio	-5.39	39.07	17.93	22.89
Price / Sales	1.87	73.72	553.92	86.28
Price / Cash	N/A	24.91	43.49	56.67
Price / Book	0.94	6.53	10.37	7.14
Net Income	-$38.94M	$158.81M	$3.57B	$335.98M
7 Day Performance	1.50%	3.72%	6.01%	3.56%
1 Month Performance	-16.00%	0.74%	3.52%	2.54%
1 Year Performance	-61.16%	3.17%	34.13%	35.05%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	2.9833 of 5 stars	$6.09 flat	$9.44 +55.1%	-61.2%	$251.90M	$134.48M	N/A	220	Analyst Upgrade
BFLY Butterfly Network	2.8922 of 5 stars	$3.86 +0.4%	$5.56 +44.3%	+105.1%	$981.60M	$97.61M	N/A	460
TNDM Tandem Diabetes Care	2.4037 of 5 stars	$13.91 +2.8%	$29.63 +113.1%	-27.8%	$953.10M	$1.03B	N/A	2,500	Gap Up
DRTS Alpha Tau Medical	2.511 of 5 stars	$10.42 +3.9%	$11.50 +10.4%	+234.7%	$916.62M	N/A	N/A	80	Earnings Report Analyst Revision
INMD InMode	1.4766 of 5 stars	$14.00 -0.7%	$16.00 +14.3%	-3.4%	$886.71M	$374.64M	10.29	480

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors

RXST vs. BFLY, TNDM, DRTS, INMD, and BVS

How does RxSight compare to Butterfly Network?

Summary

How does RxSight compare to Tandem Diabetes Care?

Summary

How does RxSight compare to Alpha Tau Medical?

Summary

How does RxSight compare to InMode?

Summary

How does RxSight compare to Bioventus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Competitors

RXST vs. BFLY, TNDM, DRTS, INMD, and BVS

How does RxSight compare to Butterfly Network?

Do analysts rate RXST or BFLY?

Does the media refer more to RXST or BFLY?

Is RXST or BFLY more profitable?

Do insiders and institutionals believe in RXST or BFLY?

Which has preferable valuation & earnings, RXST or BFLY?

Which has more volatility & risk, RXST or BFLY?

Summary

How does RxSight compare to Tandem Diabetes Care?

Do institutionals & insiders have more ownership in RXST or TNDM?

Which has higher valuation & earnings, RXST or TNDM?

Do analysts recommend RXST or TNDM?

Is RXST or TNDM more profitable?

Which has more risk & volatility, RXST or TNDM?

Does the media refer more to RXST or TNDM?

Summary

How does RxSight compare to Alpha Tau Medical?

Does the media refer more to RXST or DRTS?

Which has more risk and volatility, RXST or DRTS?

Is RXST or DRTS more profitable?

Do insiders & institutionals have more ownership in RXST or DRTS?

Do analysts recommend RXST or DRTS?

Which has preferable earnings and valuation, RXST or DRTS?

Summary

How does RxSight compare to InMode?

Is RXST or INMD more profitable?

Which has stronger valuation and earnings, RXST or INMD?

Which has more volatility and risk, RXST or INMD?

Does the media refer more to RXST or INMD?

Do insiders and institutionals have more ownership in RXST or INMD?

Do analysts prefer RXST or INMD?

Summary

How does RxSight compare to Bioventus?

Do analysts rate BVS or RXST?

Does the media prefer BVS or RXST?

Do institutionals & insiders have more ownership in BVS or RXST?

Which has more risk and volatility, BVS or RXST?

Is BVS or RXST more profitable?

Which has higher valuation and earnings, BVS or RXST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools